Tiziana Life Sciences LTD | ClinicalTrials HQ

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab	Inflammation, Neuroinflammatory Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder	Not yet recruiting	Phase 2	2026-07-07		NCT07688239
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Active, not recruiting	Phase 2	2026-07-02		NCT06292923
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)	autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy	Recruiting	Phase 2	2026-06-10		NCT06868628
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease	Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Recruiting	Phase 2	2026-02-12		NCT06489548
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis	CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Recruiting	Phase 2	2025-06-06		NCT06890923